Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px
Financing › Details

Biosun Biochemicals–BRAIN: investment, 202101 acquisition 100% €na by BRAIN AG

 

Period Period 2021-01-01
Region Region United States (USA)
Organisations Money taker Biosun Biochemicals Inc. (Biosun Flavors & Food Ingredients, Biosun FFI)
  Group BRAIN (Group)
  Money source BRAIN Biotechnology Reserarch and Information Network AG (FSE: BNN)
  Group BRAIN (Group)
Products Product food ingredient
  Product 2 food flavour
Person Person Messersmith, Mark (Biosun Biochemicals 202101 Chairman + Founder)
     

BRAIN AG. (1/7/21). "Press Release: BRAIN Group Expands Its US Products Business with the Successful Acquisition of Biosun Biochemicals Inc.". Zwingenberg.

Today, BRAIN AG announced that it has acquired Biosun Biochemicals Inc., Tampa, Florida, a successful distributor, formulator and blender of enzymes, flavors, food ingredients as well as natural colors in the US market. This acquisition will further enhance the growth trajectory of BRAIN’s BioIndustrial division and improve the distribution capabilities in North America.

BRAIN AG (B.R.A.I.N. Biotechnology Research and Information Network AG) has concluded an agreement to purchase all shares of Florida, US, based Biosun Biochemicals Inc. from founder and chairman Mark Messersmith. The transaction has closed on January 1st, 2021.

Biosun is a distributor, formulator and blender offering a full line of ingredients including: flavors, enzymes, natural colors and specialty food ingredients. Biosun is a select United States distributor for Givaudan's flavors. The company generates revenues in the low to mid-single digit million USD range and has been profitable for all of its years of operation. Further terms of the agreement will not be publicly disclosed.

The completion of this acquisition will give BRAIN an enhanced access to the large and important US market, bring many established customer relationships to the group and enhance BRAIN´s growth trajectory in North America. Biosun will continue to operate under the current company name.

Mark Messersmith, Chairman & Founder, Biosun Biochemicals Inc., states: “I have founded Biosun over 20 years ago which today is a well respected multifaceted distributor and blender of unique food ingredient formulations in the US market. With BRAIN as a successor I have now found the optimal owner to accelerate Biosun’s growth ambitions and to open a new chapter in the business development for my employees and to offer new possibilities to our valued customers.”

Lukas Linnig, CFO BRAIN AG, expresses: “We are very glad to welcome the Biosun team as a new Group member. Biosun is an acquisition, which will further enhance our growth profile, strengthen our products business and open up an improved distribution network for all BRAIN Group companies in the important US market. This bolt-on acquisition fits very well to our stated M&A strategy and has been concluded at favorable terms.”


About Biosun

Biosun Flavors and Food Ingredients is a US, Tampa Florida, based multifaceted distributor, blender and manufacturer. We offer a full line of ingredients to satisfy the specialized needs of our customer, including: flavors, processing enzymes, natural colors, FD&C colors and specialty food ingredients. Biosun FFI has formed exclusive partnerships with industry-leading companies to bring the highest quality products to our customers. We are proud to be one of the select United States distributor for Givaudan's flavors.

Biosun's mission is to achieve and maintain the highest standards of quality in the distribution and manufacture of flavor and food ingredient products. We are dedicated to supplying our customers with high quality, safe and competitive products while creating an atmosphere of exceptional customer service, including a high level of customer contact by using our staff of professional technicians and in-house analytical and pilot application laboratory. – Further informationen: www.biosunffi.com


About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe’s leading technology companies in the area of industrial biotechnology, the core discipline of the bioeconomy. As such, BRAIN identifies previously untapped efficient enzymes, microbial producer organisms and natural substances from complex biological systems, in order to make them utilizable in an industrial context. The innovative solutions and products developed by means of “Nature’s Toolbox” are successfully applied in the chemicals, cosmetics and food industries.

BRAIN's business model stands on on two pillars. The BioScience segment comprises mainly research and development business with industrial partners, and the company’s own research and development. The BioIndustrial segment consists mainly of business with industrially scalable products. As part of a growth-oriented industrialization strategy, in February 2016 BRAIN AG became the first bioeconomy company to be listed on the Prime Standard of the Frankfurt Stock Exchange. Further information is available at www.brain-biotech.com.


Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG, and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance by, and future developments at, BRAIN AG and the BRAIN Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.


Contact Media
Dr. Stephanie Konle
pr@brain-biotech.com
+49 6251 9331 70

Contact Investor Relations
Michael Schneiders
ir@brain-biotech.com
+49 6251 9331 86

   
Record changed: 2021-01-12

Advertisement

Picture Kentro Design Corporate and Web Design for Start Ups 650x80px

More documents for BRAIN (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group ChinaBio Partnerting Forum 2021 651x80




» top